In connection with the Danish national fundraiser event – Knæk Cancer – the Danish Shareholders' Association arranged a panel discussion focusing on how far we have come with cancer research from the patients' perspective.
Participants in the panel discussion:
Ole Thastrup, CSO, 2cureX
Morten Albrechtsen, CEO, FluoGuide
Morten Larsen, Equity Analyst, ABG Sundal Collier
Mikael Bak, CEO, Danish Shareholders' Association
The panel discussion (in Danish) see here
About Knæk Cancer (in Danish) see here
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com
Ole Thastrup, Chief Science Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB